

PENILEVEL 250 mg SOBRES

COMPOSTION

Per packet

Potassium phenoxymethylpenicillin250 mg (375,000 I.U.).

Excipients: Saccharose, aspartame (E 951), sodium saccharine and banana essence.

PROPERTIES

Potassium penicillin V is the potassium salt of phenoxymethylpenicillin, which has the properties of being stable in an acid medium and easily absorbed following oral intake. It is a bactericide and acts during the period of bacterial multiplication, inhibiting the biosynthesis of the mucopeptide in the cell wall.

The usual doses cause therapeutic concentrations of diverse liquids of the organism which establish their use in the indications specified.

It joins plasmaproteins by 80%. Its activity 'in vitro' among others has been proven facing the following microorganisms:

Staphylococcus sp. not producing penicillinase, streptococcus sp. (groups A, C, G, H, L and M) and diplococcus pneumoniae.

INDICATIONS

Infections caused by penicillin-sensitive germs, such as:

Infections of the respiratory system:

- Tonsillitis, septic pharyngitis, otitis
- Bronchitis and bronchopneumonia.

Moderate infections of the skin and soft tissues

- Scarlet fever, erysipelas, furuncles (boils), abscesses.

Prophylaxis of rheumatic fever and bacterial endocarditis.

In dentology

- Phlegm, stomatitis, gingivitis, prophylaxis of infections in tooth extractions.

Note: Penicillin is the chosen medicine in the treatment and prophylaxis of streptococcal infections, including prophylaxis of rheumatic fever.

DOSAGE

Dosage must be established according to the sensitivity of the causal germ and the seriousness of the infection, and must be adjusted according to the patient's clinical response.

Children

In general, 50 mg/kg of weight (75,000 I.U. / kg) a day spread over 2 or 3 intakes.

For treatment of streptococcal infections, it is recommended:

- From 1 to 5 years old: 1 packet (250 mg) every 8 hours or 2 packets (500 mg) every 12 hours, for 10 days.
- From 6 to 12 years old: 2 packets (500 mg) every 8 hours, for 10 days.

In prophylaxis of rheumatic fever or bacterial endocarditis: 1 packet (250 mg) every 12 hours.

Children over 12 years old

The usual dose for adults.

Adults

In streptococcal and staphylococcal infections: 2 packets (500 mg) every 6-8 hours, for 10 days.

Necrotizing gingivitis: 2 packets (500 mg) every 6-8 hours.

In prophylaxis of rheumatic fever and bacterial endocarditis: 1-2 packets (250-500 mg) every 12 hours.

For any infection caused by hemolytic streptococci, treatment must be prolonged for a minimum of 10 days, to avoid the appearance of acute rheumatic fever and glomerulonephritis.

GUIDELINES FOR ITS CORRECT USE

Pour the contents of the packet in approximately 20 ml of water. Shake until complete dissolution.

PENILEVEL 250 mg may be taken with meals. Nevertheless, the plasma levels are slightly higher when taken when fasting.

CONTRAINDICATIONS

Patients with a history of hypersensitivity to penicillin.

PRECAUTIONS

Must be taken with precaution in patients allergic to cephalosporins and in those with a history of allergies, mainly to medicine.

The appearance of any kind of allergic reaction means the interruption of the treatment.

WARNINGS

Warning about excipients: "This medicine contains aspartame as an excipient. People affected with phenylketonuria must take into account that every packet of this medicine contains 16.84 mg of phenylalanine".

INTERACTIONS

It must not be taken simultaneously with bacteriostatic antibiotics. Probenecid strengthens its action by decreasing its tubular secretion.

SIDE EFFECTS

Allergic reactions may occur such as urticaria and erythematous rashes. At the same time gastrointestinal disorders may occur (nausea, vomiting, diarrhea). Reversible hematic disorders (anemia, thrombocytopenia, leucopenia, coagulation disorders).

INTOXICATION AND TREATMENT

The toxicity of PENILEVEL 250 mg is very low.

In case of the appearance of an allergic reaction, treatment will be suspended and a specific therapeutic (corticoids, antihistamines, oxygen therapy, etc.) will be used.

BY PRESCRIPTION.

FINANCED BY S.N.S.

TITULAR AUTHORIZED FOR COMMERCIALIZATION

Laboratorios ERN, S.A. Pedro IV, 499-08020 Barcelona, España